Whittier Trust Co. of Nevada Inc. Raises Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

by · The Cerbat Gem

Whittier Trust Co. of Nevada Inc. lifted its stake in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,331 shares of the medical instruments supplier’s stock after acquiring an additional 761 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in West Pharmaceutical Services were worth $6,402,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in WST. Findlay Park Partners LLP lifted its holdings in West Pharmaceutical Services by 30.6% in the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock worth $236,281,000 after purchasing an additional 139,800 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its stake in West Pharmaceutical Services by 6.8% in the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 593,692 shares of the medical instruments supplier’s stock worth $195,556,000 after purchasing an additional 37,702 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 13.9% during the 1st quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier’s stock valued at $198,117,000 after purchasing an additional 61,247 shares during the last quarter. Sei Investments Co. grew its position in shares of West Pharmaceutical Services by 12.7% during the second quarter. Sei Investments Co. now owns 401,026 shares of the medical instruments supplier’s stock valued at $132,095,000 after purchasing an additional 45,208 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in West Pharmaceutical Services by 9.8% during the second quarter. Envestnet Asset Management Inc. now owns 301,339 shares of the medical instruments supplier’s stock valued at $99,258,000 after buying an additional 26,947 shares during the last quarter. 93.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now directly owns 1,478 shares in the company, valued at $443,400. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Price Performance

Shares of WST stock traded down $5.56 on Monday, reaching $287.76. The company’s stock had a trading volume of 175,041 shares, compared to its average volume of 550,030. The stock’s fifty day simple moving average is $299.96 and its 200-day simple moving average is $324.52. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $20.87 billion, a price-to-earnings ratio of 41.08, a price-to-earnings-growth ratio of 10.46 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 1 year low of $265.00 and a 1 year high of $413.70.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The company had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. During the same period in the prior year, the firm posted $2.11 earnings per share. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year. Analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Stories